WEDNESDAY, June 25, 2025 (HealthDay News) — The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type 2 diabetes, according to a study published online June 21 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, […]
The post ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes first appeared on Physician’s Weekly.
